Prediction of prostate cancer Gleason score upgrading from biopsy to radical prostatectomy using pre-biopsy multiparametric MRI PIRADS scoring system

Saeed Alqahtani1,2,5, Cheng Wei1,6, Yilong Zhang2, Magdalena Szewczyk-Bieda3, Jennifer Wilson4, Zhihong Huang2 & Ghulam Nabi1 ✉

An increase or ‘upgrade’ in Gleason Score (GS) in prostate cancer following Transrectal Ultrasound (TRUS) guided biopsies remains a significant challenge to overcome. To evaluate whether MRI has the potential to narrow the discrepancy of histopathological grades between biopsy and radical prostatectomy, three hundred and thirty men treated consecutively by laparoscopic radical prostatectomy (LRP) between July 2014 and January 2019 with localized prostate cancer were included in this study. Independent radiologists and pathologists assessed the MRI and histopathology of the biopsies and prostatectomy specimens respectively. A multivariate model was constructed using logistic regression analysis to assess the ability of MRI to predict upgrading in biopsy GS in a nomogram. A decision-analysis curve was constructed assessing impact of nomogram using different thresholds for probabilities of upgrading. PIRADS scores were obtained from MRI scans in all the included cases.

In a multivariate analysis, the PIRADS v2.0 score significantly improved prediction ability of MRI scans for upgrading of biopsy GS (p = 0.001, 95% CI [0.06–0.034]), which improved the C-index of predictive nomogram significantly (0.90 vs. 0.64, p < 0.05). PIRADS v2.0 score was an independent predictor of postoperative GS upgrading and this should be taken into consideration while offering treatment options to men with localized prostate cancer.

Histology from biopsies categorised into Gleason score is the only confirmatory test for cancer diagnosis and is most commonly used for risk stratification of men with a recent diagnosis of prostate cancer. Based on this men are counselled for various treatment options. MR imaging data is not considered in risk stratification at present. With increasing therapeutic options available to men with a diagnosis of prostate cancer, scrutiny of information from biopsy grade becomes increasingly important. There is around 35.5% (range: 14–51%) upgrading of biopsy GS in LRP1. Many factors contribute to the discrepancy between needle biopsy and corresponding radical surgery GS. Under calling of Gleason cribriform Gleason pattern 4 as pattern 3 or the presence of borderline grades due to barely appreciable glandular differentiation under microscope and lack of sampling of tertiary grade disease on biopsies are known contributors. Factors such as age, size of prostate, extent of cancer on biopsy needle and number of biopsy samples (extended/ or mapping) have also been known to impact on the incidence of upgrading2.

In light of a number of studies reporting upgrading or under-grading of prostate cancer on needle biopsies, there is the potential for under treatment or overtreatment (i.e. radiotherapy and hormone duration). Several publications3,4 and consensus updates on the Gleason grading system have partially addressed this issue including recommendation of deriving GS by adding the most common and highest Gleason pattern on biopsy rather than

1Division of Imaging Sciences and Technology, School of Medicine, Ninewells Hospital, University of Dundee, Dundee, UK. 2School of Science and Engineering, University of Dundee, Dundee, UK. 3Department of Clinical Radiology, Ninewells Hospital, Dundee, UK. 4Department of Pathology, Ninewells Hospital, Dundee, UK. 5Department of Radiological sciences, college of applied medical science, Najran University, Najran, Saudi Arabia. 6These authors contributed equally: Saeed Alqahtani and Cheng Wei. ✉e-mail: g.nabi@dundee.ac.uk
original method of adding the primary and second most common patterns\textsuperscript{5}. Moreover, upgrading if suspected, has long-term outcome implications. Corcoran \textit{et al.}\textsuperscript{6} have shown that even after adjusting for known preoperative variables (including clinical stage, prostate-specific antigen (PSA), number of positive cores and percentage of positive cores) upgrade to a higher Gleason Score (GS) remained a strong and independent predictor of biochemical recurrence after attempted local curative therapy, this underscores the importance of gaining more information to predict upgrading of biopsy GS in men diagnosed with prostate cancer as this may serve as a marker of biologically aggressive disease.

Pre-biopsy MRI has recently been shown to hold great promise in the detection and characterisation of prostate cancer\textsuperscript{7}. A negative scan (no lesion seen on the MRI scan) showed a high negative predictive value for the presence of significant prostate cancer\textsuperscript{8}. Song \textit{et al.}\textsuperscript{9} reported a high predictive value of PIRADS v2 in predicting upgrading of GS from biopsy, however this study was retrospective and MR Imaging was obtained at least 3 weeks following biopsies - an approach known to impact interpretation of images. Post-biopsy haemorrhage is the most common false-positive finding for prostate cancer\textsuperscript{10}. In this study, there was no attempt to align histopathological sectioning to MRI using recently reported 3D-mould technology. Therefore, this is the first report describing predictive accuracy of pre-biopsy MRI in upgrading biopsy GS following LRP using patient-specific 3D moulds to ensure permitted alignment of excised prostates with MRI scans.

patients and methods

Study population. This is a study with prior Caldicott institutional approval (Caldicott/IGTCAL5626). All experiments including the study protocol study followed approved institutional guidelines. The study had ethical approval (14/ES/1070) with each participant informed consenting to the use of their imaging data. Between July 2014 and January 2019, 330 men consecutively treated by LRP who were diagnosed with localised prostate cancer with raised PSA or/and abnormal digital rectal examination were included in this study. They were offered mpMRI and those with positive MRI results (PIRADS score 3 and above) were performed transrectal ultrasound (TRUS)-guided prostate biopsy (12 cores) followed. Of these patients, eight were excluded because of contraindication to MRI such as a heart pacemaker and metallic foreign body including three claustrophobic patients. Further analysis included remaining 322 patients (Fig. 1). The clinical, pathological and imaging factors information of the patients, including age, weight, preoperative PSA, PSA density, number of positive cores, maximum percentage of cancer per core and PIRADS v2 score on multiparametric MRI (mpMRI) were recorded. GS upgrading defined as a biopsy GS increasing from lower to higher grade on reported before\textsuperscript{2}. Table 1 summarises the baseline characteristics between upgraded and non-upgraded groups of the cohort.

Hypotheses of the study. We hypothesised that pre-biopsy MRI with PIRADS classification of suspicious area in prostatic cancer improve prediction of GS upgrading from biopsy to radical prostatectomy. Upgrading of GS on histology was defined as change of GS from lower to higher grade between biopsy and histology from radical prostatectomy.

MRI protocol and PIRADS score. All patients’ mpMRI scans were performed on 3 T scanner (TIM Trio, Siemens, Erlangen, Germany) 2 weeks before TRUS-guided biopsies. The mpMRI protocol was derived from the European Society of Uro-radiology Guidelines 2012 for the detection of prostate cancer and the subsequent
Table 1. Patient characteristics.

| Number of patients | Total | Upgrading | No upgrading |
|--------------------|-------|-----------|-------------|
| Age (y), mean ± SD (range) | 66.83 ± 5.9(44–77) | 66.82 ± 6.12(49–77) | 66.85 ± 5.9(44–77) |
| Prostate Weight mean ± SD (range) | 63.7 ± 30.13(12–207) | 65.3 ± 26.2(20–155) | 63.1 ± 31.78(12–207) |
| PSA level (ng/ml), mean ± SD (range) | 11.1 ± 7.39(0.1–47.7) | 12.6 ± 9.98(2–47.7) | 10.39 ± 5.7(0.1–41) |
| PSA Density (ng/ml²), mean ± SD (range) | 0.261 ± 0.234(0.001–3.48) | 0.212 ± 0.183(0.035–1.11) | 0.203 ± 0.254(0.00198–3.48) |
| Number of positive cores | 4.8 ± 3.4(1–12) | 4.1 ± 3.07(1–12) | 5.08 ± 3.42(1–12) |
| Maximum percentage of cancer per core | 50.2 ± 30.4(5–100) | 42.5 ± 30.6(5–100) | 53.3 ± 29.52(5–100) |
| PIRADS from mpMRI Benign (1,2) | 17 (5%) | 4 (4%) | 13 (6%) |
| PIRADS 3 | 21 (7%) | 6 (6%) | 15 (7%) |
| PIRADS 4 | 78 (24%) | 26 (26%) | 52 (23%) |
| PIRADS 5 | 206 (64%) | 66 (65%) | 140 (64%) |

Table 2. MRI acquisition parameters.

| T1WI | High resolution T2WI | DWI | DCE |
|------|----------------------|-----|-----|
| Axial | Sagittal | Axial | Coronal | DWI | DWI high b-value | Dyn Gd-MRI |
| TR (ms) | 650 | 6000 | 4000 | 5000 | 3300 | 3300 | 4.76 |
| Sequence | 2DTSE | 2DTSE | 2DTSE | 2DEPI | 2DEPI | 3D VIBE |
| TE (ms) | 11 | 102 | 100 | 100 | 95 | 95 | 2.45 |
| Flip angle (°) | 150 | 140 | 150 | 150 | — | — | 10 |
| Slice thickness (mm) | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Slice gap (mm) | 0.6 | 0.6 | 0.6 | 0.6 | 0 | 0 | 0.6 |
| Resolution (pixels) | 320 | 320 | 320 | 320 | 192 | 192 | 192 |
| FOV (mm) | 200 | 200 | 200 | 200 | 280 | 280 | 280 |
| b-values (s/mm²) | — | — | — | — | 50,100,500,1000 | 2000 | — |
| Temporal resolution (s) | — | — | — | — | — | — | 4 |

Histopathology data and analysis. The biopsy results were analysed by experienced pathologists; who were blinded to MRI findings. The GS for each patient was obtained. The radical prostate specimens for histology were sliced in patient-specific moulds to aid orientations between imaging and histology, which were fabricated using a 3D printer as described by our group and others previously12,13. Specifically, patient specific 3D printed moulds were made prior to surgery based on the T2-weighted MRI prostate capsule the moulds were customised for each patient using MIMICS and Solidworks. Moulds were printed at 200 micro resolution using a consumer grade 3D printer (MakerBot Replicator 5th generation). The average mould required 120 minutes to design, 4 to 7 hours to print and an expense for materials of less than $712.

Statistical analysis. Baseline characteristics of patients and pathological outcomes were compared using a chi-square test for categorical data (PIRADS score) and a Student t-test or ANOVA for continuous data (age, weight, PSA level, PSAD, number of positive cores and maximum percentage of cancer per core). Univariate logistic regression was applied to investigate the association of clinical variables with the upgrading of biopsy GS. Variables with P < 0.05 in the univariate analysis were further assessed using a multivariate logistic regression analysis to identify factors predictive of GS upgrading. In order to estimate the area under the curve (AUC) for predicting GS upgrading to determine the diagnostic performance of clinical variables with or without PIRADS score, a receiver operating characteristic (ROC) curve analysis was conducted.

In addition, logistic regression model coefficients were used to perform a nomogram predicating the probability of GS upgrading. Non-informative or non-significant variables in univariate logistic regression for GS upgrading were removed. The value of concordance indexes (c-index) were calculated and compared. The bias-corrected calibrated values were generated from internal validation based on 200 bootstrap resamples.

A decision-analysis curve was constructed assessing impact of nomogram using different thresholds probabilities of upgrading (none of the GS upgrade to all GS upgrade).
Analyses were performed using SPSS 22 (IBM Corporation, New York, US) and R software. The alpha level was set at 0.05 to determine two-tailed significance.

Results

Upgrading cohort characteristics. In total, 322 men were included in our study. Table 3 shows the concordance between the biopsy and prostatectomy Gleason score sums. Of these, (102/322; 31.6%) had GS upgrading from biopsy to LRP. Almost half of this upgrading was from biopsy GS $\leq 6$ disease (56/102; 55%). More than half of whole cohort (175/322; 54%) had a GS $7$ on prostate biopsy and (30/175; 17%) men had GS upgrading. Finally, eighty five of the cohort (85/322; 26%) had a GS $\geq 8$ on prostate biopsy and (16/85; 18.8%) men had GS upgrading from GS 8 on prostate biopsy to GS $> 8$ at LRP.

The correlation between PIRADS score and pathologic GS at LRP is demonstrated in Fig. 3. Of the 322 patients, the distribution of PIRADS score was as follows: score 1 and 2 in 17 (17/322; 5%) patients, score 3 in 21 (21/322; 7%) patients, score 4 in 78 (78/322; 24%) patients, and score 5 in 206 (206/322; 64%) patients.

Predictions of GS upgrading. Table 4 shows the outcomes of the logistic regression analysis and predictive variables of GS upgrading. On univariate analyses, increased preoperative PSA levels, number of positive cores, maximum percentage of cancer per core and PIRADS $\geq 4$ were all significantly associated with GS upgrading ($p < 0.05$). Age, weight of prostate and PSAD did not show any significance ($p > 0.05$) which were excluded from further analyses. In the multivariate analyses, PIRADS $\geq 4$ and higher PSA level were both statistically significant and independently predictive of GS upgrading ($p = 0.001$ and 0.003, respectively).

In Fig. 4, PIRADS v2 score with PSA value show a higher accuracy than PSA alone for predicting GS upgrading (AUC = 0.90 and 0.64, respectively, $p < 0.001$).

Impact of PIRADS score on prediction of GS upgrading in relation to other factors. Figure 5a,5b show the nomograms constructed for upgrading of biopsy GS with and without PIRADS v2 score data. Longer scales indicated higher percentage of impact and larger points were suggesting probability of upgrading. PIRADS score had the greatest impact followed by PSA level. C-index of the established nomogram which had PIRADS v2 score variable to predict the GS upgrading in the cohort was significantly higher than that of the nomogram.
without PIRADS score (0.90 [95% CI 0.87–0.89] vs. 0.64 [95% CI, 0.57–0.70], p = 0.001). The nomograms were then validated using 200 bootstrap samples, internal calibration curves are shown in Fig. 5b1,b2.

Decision curve analysis. The decision analysis curve is shown in Fig. 6. The net benefit for the model using PIRADS score was significantly higher at all thresholds compared with the model without PIRADS score. As seen in Fig. 6, the decision curve line (depicted by a red line) of the model without the PIRADS scores remained close to the line with threshold probabilities ranging from 0 to 0.25. In contrast, a higher positive net benefit was obtained in the range of threshold probabilities ranging from 0.05 to 1.0 in the model with PIRADS scores.

Discussion

Principal findings of the study. This is the first study to bring together information of PIRADS scores in pre-biopsy MRI and an improved image oriented histopathological grossing of RP specimen by making the use of the mould, bridging the gap in the existing literature. Our results indicate a significant advantage (C-index 0.90 vs 0.64) of using the prediction model including PIRADS scores added to conventional clinic-pathological characteristics (PSA level, percentage of cancer on core-biopsies, gland size etc.) of men with prostate cancer confirmed by systematic transrectal random biopsies relative to a model without PIRADS scores. Prostate biopsy GS upgrading remains a challenge for physicians managing localised prostate cancer, as better knowledge of contributing factors and how to narrow the gap is lacking. To inform any consensus, we need an improved understanding of the role imaging can play, in particular pre-biopsy MRI, in predicting GS change and adverse downstream oncological outcomes. Although, recent improvements have been made in refining biopsy strategies and in reducing sampling errors, a significant and continued effort is still needed to identify men at risk of GS upgrading.

Study findings in context of the reported literature. Wang JY et al.14 reported a nomogram with C-index of 0.795 using preoperative factors without imaging data in a non-screened population from China. This is similar to our study as the healthcare system for the cohort reported here did not have men screened for prostate cancer. Table 5 shows the predictive ability of various reported nomograms in upgrading of biopsy GS of prostate cancer in screened populations14–17. The upgrading rate of biopsy GS seen in our cohort is similar to a larger cohort of 2982 patients reported previously15. A higher percentage of men with a GS of 6 were upgraded in the present study. It is interesting that despite the higher number of cores obtained in the present study (12 in

---

Table 4. Univariate and multivariate logistic regression analysis.

|                     | Univariate                  | Multivariate               |
|---------------------|-----------------------------|----------------------------|
|                     | OR (95% CI)                 | P-value                    |
|                     | P                     | OR (95% CI)               | P-value     |
| Age                 | 1.005 (0.962–1.041)        | 0.799                      |
| Pathology weight    | 1.002(0.931–1.009)         | 0.540                      |
| Number of positive cores | 0.86(0.87–0.96)        | 0.005                      |
| PSA level (ng/ml)   | 1.040 (1.009–1.073)        | 0.001                      |
| PSA Density (ng/ml³) | 1.15 (0.44–3.04)     | 0.76                       |
| Maximum percentage of cancer per core | 0.988 (0.980–0.96) | 0.002                      |
| PIRADS               |                           |                           |
| ≤ 3                 | 1 (reference)              | —                          |
| > 3                 | 0.017(0.08–0.04)           | 0.001                      |

Figure 3. Radical prostatectomy Gleason score stratified according to PIRADS score.
A number of previous studies have carried out multivariate analyses of factors responsible for upgrading of biopsy GS including construction of nomograms (Table 5). In predictive oncology, nomograms have huge
potential to help clinicians determine the risk of disease progression and identify those who would experience a greater benefit from multimodality therapy. This approach may result in avoiding unnecessary treatment and improve quality of life by reducing side effects of therapy through better and more precise approach. However, a careful approach is needed to construct nomogram based on specific question, the study population, the method of construction, and its ability to apply to a particular clinical situation. We have followed guidelines described in previous publications18–20 in constructing nomogram in this study including selection of variables and statistical methods. The nomogram in the present study has been internally validated (Cross-validation and bootstrapping). External validation of nomogram was not carried out in the present study as this would require further prospective multi-centre recruitment of a cohort. Since D’Amico pioneered this approach21, none of the reported predictive nomograms have included imaging features of the disease. Furthermore, the advantage of our nomogram is a higher overall accuracy (discriminant properties) and closer agreement between predicted and observed values (superior calibration). Estimating clinical utility of nomograms in prognosticating an outcome of intervention remains core value of translational research in precision medicine. Vickers and Elkin22 have introduced decision analysis curves estimating probabilities of benefits and harms that a diagnostic test or intervention can trigger at various thresholds. Addition of PIRADS score to nomogram achieved a higher net benefit of decisions making in comparison to leaving out PIRADS score as shown in the decision analysis curve constructed in the present study. The thresholds ranged from no upgrading of disease to all men having upgrading of disease following LRP.

Clinical implications of the study findings. Predicting final histopathological Gleason score of prostate cancer remains a highly desirable information for physicians counselling men with localised prostate cancer for various modalities of treatment and long-term disease recurrence. At present, various nomograms are used mainly taking into consideration clinical factors such as age, pre-operative PSA level and number of biopsy cores involved with the cancer. Notwithstanding this, there is still a large histopathological discrepancy between biopsy and final radical prostatectomy Gleason score. The present study reports a nomogram based on pre-biopsy multiparametric MRI grade (PIRADS score) of cancer alongwith other known clinical parameters. The nomogram clearly showed an improved prediction of final Gleason score and the findings have a large implications for clinicians and researchers in this area. We envisage that this and further research should take us close to precise prediction of final Gleason score of histopathology in prostate cancer and thereby an improved and informed decision making by stakeholders including patients in the management of localised prostate cancer. This will have huge benefits for improved GS prediction for men opting for active surveillance and focal therapy besides those opting for radical prostatectomy.

Table 5. literature review and comparison between previous and current studies.

| Author        | year | Number of patients | Performance (C-index) | Significant parameters on multivariate analysis                                      |
|---------------|------|--------------------|-----------------------|---------------------------------------------------------------------------------------|
| Chun, FK      | 2006 | 2982               | 0.804                 | PSA level, clinical stage and primary and secondary GS                                |
| Kulkarni, GS  | 2007 | 175                | 0.71                  | PSA level and the level of pathologist expertise                                      |
| Budäus, L     | 2010 | 414                | 0.708                 | PSA level, clinical stage, prostate volume and percent of positive cores               |
| Wang, YJ      | 2014 | 220                | 0.789                 | PSA level, clinical stage, and primary and secondary GS                                |
| Biming, He    | 2016 | 411                | 0.753                 | Primary and secondary GS and obesity                                                  |
| This study    | 2019 | 322                | 0.90                  | PSA level and PIRADS score on mp-MRI                                                 |
Limitation of the study. There are limitations to our study. This is a single centre study with dedicated uro-radiologist and pathologist, and the rate of upgrading may be different in small centres. Moreover, overall accuracy of our model, although higher than previous was not perfect (90%). Additionally, performance of our model needs further validation in an external data set. Finally, the novelty of our model could still be improved by integrating additional predictor variables, such as the novel genomic and other biomarkers. The growing field of artificial intelligence and machine learning using radiomics approach may improve our ability to define tumour characteristics and classification. This, undoubtedly may impact results of the study in the future. Finally, with emerging evidence supporting MRI facilitated biopsy targeting of suspicious areas using ultrasound, the rate of upgrading and the future implications for the practice may change. There is an emerging evidence that targeted biopsy may improve our ability to narrow the upgrading gap between the biopsies and radical prostatectomy histology; however no predictive nomogram information was available from both the studies. Our ongoing work through randomised intervention in MR/US fusion should be able to provide more information.

In Conclusions, PIRADS version 2 score of 4 or 5 are associated with an increased risk of biopsy Gleason Score upgrading. Pre-biopsy MRI and PIRADS score significantly and independently predict GS upgrading. If proven by external validation, this information should help in decision making by offering treatment options to men with localised prostate cancer.

Received: 13 January 2020; Accepted: 7 April 2020;
Published online: 07 May 2020

References
1. Budäus, L. et al. The novel nomogram of Gleason sum upgrade: Possible application for the eligible criteria of low dose rate brachytherapy. Int. J. Urol. 17, 862–868 (2010).
2. Epstein, J. I., Feng, Z., Trock, B. J. & Pierorazio, P. M. Upgrading and Downgrading of Prostate Cancer from Biopsy to Radical Prostatectomy: Incidence and Predictive Factors Using the Modified Gleason Grading System and Factoring in Tertiary Grades. Eur. Urol. 61, 1019–1024 (2012).
3. Amin, M. M. et al. Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scand. J. Urol. Nephrol. Suppl. 39, 20–33 (2005).
4. Epstein, J. I. et al. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am. J. Surg. Pathol. 29, 1228–1242 (2005).
5. Garnett, J. E., Oyasu, R. & Grayhack, J. T. The accuracy of diagnostic biopsy specimens in predicting tumor grades by Gleason's classification of radical prostatectomy specimens. J. Urol. 131, 690–693 (1984).
6. Corcoran, N. M. et al. Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU Int. 108, 202–210 (2011).
7. Ahmed, H. U. et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet (London, England) 389, 815–822 (2017).
8. Itatani, R. et al. Negative predictive value of multiparametric MRI for prostate cancer detection: Outcome of 5-year follow-up in men with negative findings on initial MRI studies. Eur. J. Radiol. 83, 1740–1745 (2014).
9. Song, W. et al. Role of PI-RADS Version 2 for Prediction of Upgrading in biopsy-Proven Prostate Cancer With Gleason Score 6. Clin. Genitourin. Cancer 16, 281–287 (2018).
10. White, S. et al. Prostate Cancer: Effect of Postbiopsy Hemorrhage on Interpretation of MR Images' From the Departments of Radiology. Radiology 195, 385–390 (1995).
11. Padhani, A. R. et al. Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions. Eur. Urol., https://doi.org/10.1016/J.EURURO.2018.05.035 (2018).
12. Sheikh, N. et al. Combined T2 and diffusion-weighted MR imaging with template prostate biopsies in men suspected with prostate cancer but negative transrectal ultrasound-guided biopsies. World J. Urol. 35, 213–220 (2017).
13. Wei, C. et al. Quantitative parameters in dynamic contrast-enhanced magnetic resonance imaging for the detection and characterisation of prostate cancer. Oncotarget 9, 15997–16007 (2018).
14. Wang, J. Y. et al. A nomogram to predict gleason sum upgrading of clinically diagnosed localized prostate cancer among Chinese patients. Chin. J. Cancer 33, 241–248 (2014).
15. Chua, F. K.-H. et al. Development and Internal Validation of a Nomogram Predicting the Probability of Prostate Cancer Gleason Sum Upgrading Between Biopsy and Radical Prostatectomy Pathology. Eur. Urol. 49, 820–826 (2006).
16. Kulkarni, G. S. et al. Clinical predictors of gleason score upgrading. Cancer 109, 2432–2438 (2007).
17. He, B. et al. Nomograms for predicting Gleason upgrading in a contemporary Chinese cohort receiving radical prostatectomy after extended prostate biopsy: development and internal validation. Oncotarget 7 (2016).
18. Iasonos, A., Schrag, D., Raj, G. V. & Panagia, K. S. How to build and interpret a nomogram for cancer prognosis. J. Clin. Oncol. 26, 1364–1370 (2008).
19. Harrell, F. E. Regression Modeling Strategies [electronic resource]: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis in Springer Series in Statistics. Springer (2015).
20. Balanchandran, V. P., Gonen, M., Smith, J. J. & DeMatteo, R. P. Nomograms in oncology: More than meets the eye. J. Clin. Oncol. 16, e175–e180 (2015).
21. D'Amico, A. V. et al. The Combination Of Preoperative Prostate Specific Antigen And Postoperative Pathological Findings To Predict Prostate Specific Antigen Outcome In Clinically Localized Prostate Cancer. J. Urol. 160, 2096–2101 (1998).
22. Vickers, A. J. & Elkin, E. B. Decision curve analysis: A novel method for evaluating prediction models. Med. Decis. Mak. 26, 565–574 (2006).
23. Kornberg, Z., Cooperberg, M. R., Spratt, D. E. & Feng, F. Y. Genomic biomarkers in prostate cancer. Transl. Androl. Urol. 7, 459–471 (2018).
24. Sanhueza, C. & Kohli, M. Clinical and Novel Biomarkers in the Management of Prostate Cancer. Curr. Treat. Options Oncol. 19 (2018).
25. Kavisivathan, V. et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N. Engl. J. Med. 378, 1767–1777 (2018).
26. Nassiri, N. et al. Targeted Biopsy to Detect Gleason Score Upgrading during Active Surveillance for Men with Low versus Intermediate Risk Prostate Cancer. J. Urol. 197, 632–639 (2017).
27. Le, J. D. et al. Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology. J. Urol. 192, 1367–1373 (2014).
28. Szewczyk, Rieda, M. et al. A multicentre parallel-group randomised trial assessing multiparametric MRI characterisation and image-guided biopsy of prostate in men suspected of having prostate cancer: MULTIPROS study protocol. Trials 20, 638 (2019).
Acknowledgements
Thanks to Dr. Chunhui Li and Yuting Ling for providing the row image (Biopsy tissue sample).

Author contributions
All authors had input into the manuscript and have approved the manuscript for publication. Conceptualization, G.N. and C.W.; methodology, C.W.; validation, M.S.B., J.W. and Z.H.; formal analysis, Y.Z.; investigation, C.W.; resources, S.A., M.S.B., J.W.; writing—original draft preparation, S.A.; writing—review and editing, C.W. Z.H., G.N.; visualization, S.A.; supervision, G.N.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to G.N.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020